Activation of α2 adrenoceptor attenuates lipopolysaccharide-induced hepatic injury

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 9, 2015, Pages 10752-10759

  Chen, Jing Hui ^a   Yu, Gao Feng ^a   Jin, Shang Yi ^b   Zhang, Wen Hua ^a   Lei, Dong Xu ^a   Zhou, Shao Li ^b   Song, Xing Rong ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Dexmedetomidine; Liver injury; Sepsis; Yohimbine; 2 adrenoceptor agonist

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ASPARTATE AMINOTRANSFERASE; BETA 2 ADRENERGIC RECEPTOR; BIOLOGICAL MARKER; DEXMEDETOMIDINE; IL1B PROTEIN, RAT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTIC ACID; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE, ESCHERICHIA COLI O111 B4; MALONALDEHYDE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR; YOHIMBINE;

ANIMAL; BLOOD; CELL PROTECTION; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; LIVER; MALE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; SEPSIS; SPRAGUE DAWLEY RAT; TIME FACTOR;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BIOMARKERS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CYTOPROTECTION; DEXMEDETOMIDINE; DISEASE MODELS, ANIMAL; INTERLEUKIN-1BETA; INTERLEUKIN-6; LACTIC ACID; LIPOPOLYSACCHARIDES; LIVER; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA-2; SEPSIS; SUPEROXIDE DISMUTASE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOHIMBINE;

EID: 85012991848     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348; 1546-1554.
2. Hartman ME, Linde-Zwirble WT, Angus DC, Watson RS. Trends in the Epidemiology of Pediatric Severe Sepsis. Pediatr Crit Care Med 2013; 14: 686-693.
3. Dhainaut JF, Marin N, Mignon A, Vinsonneau C. Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med 2001; 29: S42-47.
4. Russell JA, Walley KR. Update in sepsis 2012. Am J Respir Crit Care Med 2013; 187: 1303-1307.
5. Giamarellos-Bourboulis EJ. The failure of biologics in sepsis: where do we stand? Int J Antimicrob Agents 2013; 42 Suppl: S45-47.
6. Anger KE, Degrado JR, Greenwood BC, Cohen SA, Szumita PM. Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center. Ther Clin Risk Manag 2013; 9: 277-284.
7. Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way? Crit Care Med 2012; 40: 2704-2708.
8. MacLaren R. Immunosedation: a consideration for sepsis. Crit Care 2009; 13: 191.
9. Sanders RD, Hussell T, Maze M. Sedation & immunomodulation. Crit Care Clin 2009; 25: 551-70, ix.
10. Tasdogan M, Memis D, Sut N, Yuksel M. Results of a pilot study on the effects of propofol and dexmedetomidine on inflammatory responses and intraabdominal pressure in severe sepsis. J Clin Anesth 2009; 21: 394-400.
11. Pandharipande PP, Sanders RD, Girard TD, McGrane S, Thompson JL, Shintani AK, Herr DL, Maze M, Ely EW, investigators M. Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. Crit Care 2010; 14: R38.
12. Arslan M, Metin Comu F, Kucuk A, Ozturk L, Yaylak F. Dexmedetomidine protects against lipid peroxidation and erythrocyte deformability alterations in experimental hepatic ischemia reperfusion injury. Libyan J Med 2012; 7.
13. Hsing CH, Lin CF, So E, Sun DP, Chen TC, Li CF, Yeh CH. Alpha2-Adrenoceptor agonist dexmedetomidine protects septic acute kidney inju-ry through increasing BMP-7 and inhibiting HDAC2 and HDAC5. Am J Physiol Renal Physiol 2012; 303: F1443-1453.
14. Sezer A, Memis D, Usta U, Sut N. The effect of dexmedetomidine on liver histopathology in a rat sepsis model: an experimental pilot study. Ulus Travma Acil Cerrahi Derg 2010; 16: 108-112.
15. Ibacache M, Sanchez G, Pedrozo Z, Galvez F, Humeres C, Echevarria G, Duaso J, Hassi M, Garcia L, Diaz-Araya G, Lavandero S. Dexmedetomidine preconditioning activates pro-survival kinases and attenuates regional ischemia/reperfusion injury in rat heart. Biochim Biophys Acta 2012; 1822: 537-45.
16. Zhang F, Wu R, Qiang X, Zhou M, Wang P. Antagonism of alpha2A-adrenoceptor: a novel approach to inhibit inflammatory responses in sepsis. J Mol Med (Berl) 2010; 88; 289-296.
17. Delladetsima I, Psichogiou M, Alexandrou P, Nikolopoulos G Revenas K, Hatzakis A, Boletis J. Apoptosis and hepatitis C virus infection in renal transplant recipients. Am J Clin Pathol 2008; 129: 744-748.
18. Jaramillo-Bustamante JC, Marin-Agudelo A, Fernandez-Laverde M, Bareno-Silva J. Epidemiology of sepsis in pediatric intensive care units: first Colombian multicenter study. Pediatr Crit Care Med 2012; 13: 501-508.
19. Moore LJ, Moore FA. Epidemiology of sepsis in surgical patients. Surg Clin North Am 2012; 92: 1425-1443.
20. Spapen H. Liver perfusion in sepsis, septic shock, and multiorgan failure. Anat Rec (Hoboken) 2008; 291: 714-720.
21. Asfar P, De Backer D, Meier-Hellmann A, Radermacher P, Sakka SG. Clinical review: influence of vasoactive and other therapies on intestinal and hepatic circulations in patients with septic shock. Crit Care 2004; 8: 170-179.
22. Galley HF. Oxidative stress and mitochondrial dysfunction in sepsis. Br J Anaesth 2011; 107: 57-64.
23. Jansen TC, van Bommel J, Woodward R, Mulder PG, Bakker J. Association between blood lactate levels, Sequential Organ Failure Assessment subscores, and 28-day mortality during early and late intensive care unit stay: a retrospective observational study. Crit Care Med 2009; 37: 2369-2374.
24. Kang YR, Um SW, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ, Jeon K. Initial lactate level and mortality in septic shock patients with hepatic dysfunction. Anaesth Intensive Care 2011; 39: 862-867.
25. Walker CA, Griffith DM, Gray AJ, Datta D, Hay AW. Early lactate clearance in septic patients with elevated lactate levels admitted from the emergency department to intensive care: Time to aim higher? J Crit Care 2013; 28: 832-837.
26. Yang CL, Tsai PS, Huang CJ. Effects of dexmedetomidine on regulating pulmonary inflammation in a rat model of ventilator-induced lung injury. Acta Anaesthesiol Taiwan 2008; 46: 151-159.
27. Okada H, Kurita T, Mochizuki T, Morita K, Sato S. The cardioprotective effect of dexmedetomidine on global ischaemia in isolated rat hearts. Resuscitation 2007; 74: 538-545.
28. Romero-Sandoval A, Eisenach JC. Clonidine reduces hypersensitivity and alters the balance of pro-and anti-inflammatory leukocytes after local injection at the site of inflammatory neuritis. Brain Behav Immun 2007; 21: 569-580.
29. Lavand'homme PM, Eisenach JC. Perioperative administration of the a2-adrenoceptor agonist clonidine at the site of nerve injury reduces the development of mechanical hype-rsensitivity and modulates local cytokine expression. Pain 2003; 105: 247-254.
30. Yang S, Zhou M, Chaudry IH, Wang P. Norepinephrine-induced hepatocellular dysfunction in early sepsis is mediated by activation of alpha2-adrenoceptors. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1014-1021.
31. Weatherby KE, Zwilling BS, Lafuse WP. Resistance of Macrophages to Mycobacterium avium Is Induced by 2-Adrenergic Stimulation. Infect Immun 2003; 71: 22-29.